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Biosimilars in Latin America” by Azevedo et al.I refer to the article titled “Potential regulatory and commercial
environment for biosimilars in Latin America” written by Aze-
vedo et al., published in Value in Health Regional Issues 1 (2012):228–
34, which contains incorrect information about biosimilars’
regulation and market environment in Mexico.
It must be emphasized that until now there have been no
reported cases of anaphylactic shock related to Kikuzubam in
Mexico or elsewhere and that there are no safety concerns with
the product. The authors based their assertion on a newspaper
article that consisted of an interview with a competitor’s execu-
tive at its facility in Palo Alto, CA [1]. The mentioned rash and
anaphylactic shock cases never existed and were never reported.
This is why Probiomed would like to explain to your distin-
guished readers that there are no Kikuzubam’s safety data
concerns published by any scientiﬁc journal or ofﬁcial commu-
nication from the Mexican health authorities supporting those
claims against the product.
In addition, we identiﬁed that the Mexican current situation
described by Sandorff et al. has several inaccuracies regarding the
regulatory framework for biotechnology drugs. The authors omit
to mention that Mexican health authorities issued a decree
amending and adding various provisions of the regulation of
health products in October 2011 [2].
Although Sandorff et al. mentioned that phase III comparative
trials may not be required for biosimilars and the main factor
inﬂuencing the decision will be the product type, the regulation
cited above describes how biotechnology products require phar-
macokinetics, pharmacodynamics, safety, and efﬁcacy clinical
trials. Kikuzubam complied with all these requirements.
The safety and scientiﬁc requirements endorsed in the Emer-
gency Mexican Ofﬁcial Standard NOM-EM-001-SSA1-2012 for
biotechnology drugs and biopharmaceuticals published in Sep-
tember 2012 include Good Manufacturing Practices compliance,
technical and scientiﬁc safety, efﬁcacy and quality proof, labeling,
and requirements for biocomparability studies and active phar-
macovigilance [3].
Mexican health authorities’ initiatives conﬁrm that the new
biosimilar registration pathway has been designed to align the
Mexican regulatory framework with International Conference of
Harmonization requirements, instead of just pretending to
increase access to biosimilars as Sandorff et al. claimed.Finally, it is a known fact that biotechnology generic drugs (as
they were called before the terms “biosimilars” or “biocompar-
ables” were coined) have been in the Mexican health system for
over 20 years.
Probiomed has developed such products since 1996; the
portfolio includes recombinant proteins, cytokines, hormones,
recombinant vaccines, monoclonal antibodies, and fusion pro-
teins. In approximately 15 years, Probiomed has supplied more
than 76 million doses of biotechnology products to health
institutions, health care professionals, and patients in Mexico
and several countries, without receiving any safety or efﬁcacy
complains.
More than 15 million patients have been exposed to Probio-
med’s biotechnology generic drugs as detailed in Table 1.
We appreciate and thank you for giving us the opportunity to
make these clariﬁcations.
Jorge Revilla Beltri, MD
Medical Director, Probiomed, Mexico D.F., Mexico
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Table 1 – Patients treated with biosimilars manufactured by Probiomed.
Probiomed biosimilar
name
A P I Original brand/
laboratory
Approval
year
Units distributed per year Total units Treated
patients†
2010* 2011 2012 2013
Gramal Molgramostim Leucomax/Sch-P 1996 157,633 3,652 227 3,654 165,166 23,595
Proquiferón Alfa 2a IFN Roferón/Roche 1996 169,492 – – – 169,492 1,412
Urifrón Alfa 2b IFN Intrón-A/Sch-P 1997 977,341 170,035 183,316 49,745 1,380,437 11,504
Bioyetin Eritropoyetin
(rHu-EPO)
Recormón/Roche 1998 12,764,557 2,198,892 2,317,365 4,887,978 22,168,792 213,161
Probivac pediatric HBv Vaccine Engerix-B/Glaxo 2000 4,532,144 3,875,000 3,927,069 7,500,000 19,834,213 6,611,404
Probivac adult HBv Vaccine Engerix-B/Glaxo 2000 17,030,081 4,969,950 1,296,456 2,500,000 25,796,487 8,598,829
Filatil Filgrastim Neupogen/Roche 2001 436,274 79,072 84,133 317,639 917,118 131,017
Protophin Somatropin Humatrope/Lilly 2001 130,294 47,424 44,016 18,000 239,734 7,882
Glinux Insulin Humulin/Lilly 2001 3,709,686 224,231 55,330 23,400 4,012,647 131,923
Uribeta Beta 1b IFN 8 MUI Betaferon/Bayer 2002 360,720 106,083 121,742 154,669 743,214 4,764
Emaxem Beta 1a IFN 12
MUI
Rebif/Merck-Se 2004 188,442 13,922 14,544 16,391 233,299 1,496
Jumtab Beta 1a IFN 6 MUI Avonex/Bayer 2006 111,244 20,883 25,852 13,575 171,554 3,299
Kikuzubam Rituximab Mabthera/Roche 2010 – 12,685 40,593 63,461 116,739 7,708
Inﬁnitam Etanercept Enbrel/W-Pﬁzer 2012 – – – 248,000 248,000 2,583
Total biosimilar
units
76,166,892
Total patients
treated
15,750,577
Note. For more than 15 years, Probiomed has offered more than 76 million doses of biosimilar products for the treatment of more than 15 million patients in Mexico and in the global market.
Probiomed has never received a report of immunogenicity or adverse events on its biosimilars, different from those reported by the original product. All Probiomed products are under strict
pharmacovigilance programs.
 From year of registration up to 2010.
† The number of patients was calculated according to current posological schemes.
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